The Delta variant (B.1.617.2) is a strain of SARS-CoV-2 that was first identified in India in late 2020 and became the dominant form of COVID-19 worldwide by mid-2021. It spread roughly twice as easily as the original virus, carried viral loads about 250 times higher in the respiratory tract, and approximately doubled the risk of hospitalization in unvaccinated people. Delta was eventually displaced by the Omicron variant in late 2021.
Where Delta Came From
The variant was first detected in India in late 2020 and spread rapidly, reaching approximately 60 countries by mid-2021. The World Health Organization designated it a “variant of concern,” and it quickly outcompeted the Alpha variant (B.1.1.7, first found in the UK) to become the globally dominant strain. Its rise coincided with devastating COVID waves in India, the UK, and eventually the United States.
Why It Spread So Easily
Delta’s average reproduction number, the number of people one infected person would spread the virus to in a fully susceptible population, was estimated at 5.08. For comparison, the original Wuhan strain had a reproduction number of about 2.79. That difference sounds modest on paper, but in practice it meant exponentially faster community spread.
Two biological changes drove this. First, mutations in the spike protein gave Delta a slightly stronger grip on human cells by improving the fit between the virus and the ACE2 receptor it uses to enter cells. Second, separate mutations helped Delta partially evade antibodies, both through direct changes at the sites where antibodies bind and through indirect structural shifts that made those sites harder for the immune system to recognize. The combination of better cell entry and partial immune escape is what allowed Delta to outpace every previous variant.
People infected with Delta also carried dramatically more virus. A study of healthcare workers in Vietnam published in The Lancet found that peak viral loads in Delta infections were 251 times higher than in people infected with the original strain in early 2020. Higher viral loads meant more virus shed with each breath, making transmission more likely in any given encounter.
Incubation Period
Delta had a mean incubation period of about 5 days from exposure to first symptoms. This was slightly shorter than the original strain’s typical window of 5 to 6 days, though the difference was not dramatic. Where timing mattered more was in how quickly viral loads peaked: people with Delta reached high levels of virus in their airways earlier in the course of illness, which contributed to its ability to spread before people realized they were sick.
How Symptoms Differed
Cough and fever remained the most common symptoms with Delta, but the overall pattern shifted compared to the original virus. A study in Frontiers in Medicine comparing Delta and wild-type infections found that Delta patients actually reported fewer symptoms overall, with notable drops in gastrointestinal complaints. Fever appeared in 36% of Delta patients versus 81% of those with the original strain. Cough dropped from 83% to 50%. Chest pain, shortness of breath, vomiting, and abdominal pain were all significantly less common.
The exception was sore throat. It appeared in 25% of Delta patients but was essentially absent in the original strain’s profile. This shift, along with reports of headache and runny nose being more prominent, led some clinicians to note that Delta could initially feel more like a bad cold than the classic COVID presentation people had learned to watch for in 2020.
Hospitalization and Severity
Despite sometimes causing milder initial symptoms, Delta was more dangerous overall. A large study of unvaccinated U.S. veterans found that Delta roughly doubled the risk of hospitalization compared to earlier strains, with a hazard ratio of 1.93. The risk of needing intensive care was even higher, with 2.29 times the odds. The risk of death increased by a factor of about 2.15. Studies from the UK and Denmark found similar patterns, with hospitalization hazard ratios of 2.32 and 3.01 respectively when comparing Delta to Alpha.
These figures all come from unvaccinated populations. Vaccination substantially changed the picture.
How Well Vaccines Held Up
Two doses of the Pfizer-BioNTech vaccine were 88% effective at preventing symptomatic Delta infection, according to a large study published in the New England Journal of Medicine. That was lower than the vaccine’s efficacy against the Alpha variant, but still strong protection against getting sick.
Protection against severe outcomes was even more robust. The Moderna vaccine showed 97.5% effectiveness against hospitalization with Delta in a study published in The BMJ. Only 3.5% of hospitalized Delta patients in that study had been fully vaccinated, compared to nearly 52% of the control group. Both mRNA vaccines maintained high effectiveness against the worst outcomes, even as their ability to prevent any infection waned over time, particularly in older adults. This waning was part of the rationale for booster doses introduced later in 2021.
How Delta Was Replaced
Delta’s dominance lasted roughly six months before the Omicron variant arrived. Omicron was first identified in late November 2021 and displaced Delta with remarkable speed. In Maryland, for example, Omicron went from less than 1% of sequenced cases in early December to the dominant strain in under three weeks. This pattern repeated globally, with Omicron’s even greater transmissibility and immune escape allowing it to overtake Delta in most countries by January 2022.
Delta’s rapid rise and fall illustrates how quickly SARS-CoV-2 variants can reshape the pandemic landscape. Each dominant variant has built on the mutations of its predecessors, and Delta’s specific combination of higher viral loads, improved cell entry, and partial antibody evasion made it the most formidable version of the virus until Omicron arrived with an even more extensively mutated spike protein.